Tasman Therapeutics

Tasman Therapeutics is a late-stage private biotech advancing R-107, a proprietary oral extended-release ketamine tablet for Treatment-Resistant Depression. With Phase 2 trials complete and an open IND for Phase 3, the company is preparing for pivotal studies with a clear regulatory pathway. As an affiliate of the established Douglas Pharmaceuticals, Tasman benefits from deep formulation expertise, strong IP protection until at least 2037, and a seasoned leadership team, positioning it to potentially capture a significant share of the growing TRD market with a convenient, at-home monotherapy.

Proprietary oral extended-release timed-delivery system for (R)-ketamine, designed to provide sustained antidepressant effect while minimizing dissociative side effects.

R-107's primary competition includes Johnson & Johnson's Spravato (esketamine nasal spray), a clinic-administered treatment, and off-label use of compounded oral ketamine. It also faces future competition from other oral psychedelics in development (e.g., psilocybin for depression) and novel rapid-acting antidepressants. Its key differentiator is the combination of oral, at-home administration with a safety profile designed to minimize dissociation.